We are live on ! Find out more

2,244 hedge funds and large institutions have $154B invested in Pfizer in 2017 Q4 according to their latest regulatory filings, with 281 funds opening new positions, 858 increasing their positions, 866 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

376% more first-time investments, than exits

New positions opened: 281 | Existing positions closed: 59

10% more funds holding

Funds holding: 2,0422,244 (+202)

2% more capital invested

Capital invested by funds: $151B → $154B (+$3.32B)

0.43% more ownership

Funds ownership: 75.05%75.48% (+0.43%)

1% less repeat investments, than reductions

Existing positions increased: 858 | Existing positions reduced: 866

8% less funds holding in top 10

Funds holding in top 10: 177163 (-14)

27% less call options, than puts

Call options by funds: $942M | Put options by funds: $1.3B

Holders
2,244
Holders Change
+202
Holders Change %
+9.89%
% of All Funds
50.78%
Holding in Top 10
163
Holding in Top 10 Change
-14
Holding in Top 10 Change %
-7.91%
% of All Funds
3.69%
New
281
Increased
858
Reduced
866
Closed
59
Calls
$942M
Puts
$1.3B
Net Calls
-$357M
Net Calls Change
-$562M

PFE Hedge Fund Activity: Q4 2017 in Review

2,244 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2017, worth a combined $154B — up 2.2% from $151B a quarter earlier.

Buyers outnumbered sellers: 281 funds opened new PFE positions and 59 closed out — a net gain of 222 holders — while 858 added to existing stakes and 866 trimmed.

The largest buyer was BlackRock, adding an estimated $438M. The largest seller was Bank of America, cutting an estimated $590M.

  • 2,244 institutional investors held Pfizer (PFE) as of Q4 2017, up from 2,042 in Q3 2017.
  • Funds reported $154B of Pfizer stock for Q4 2017, up 2.2% quarter-over-quarter.
  • 281 funds opened new Pfizer positions in Q4 2017 and 59 closed out, a net change of +222 holders.
  • The largest Pfizer buyer in Q4 2017 was BlackRock, an estimated $438M added.
  • The largest Pfizer seller in Q4 2017 was Bank of America, an estimated $590M sold.

Based on aggregated 13F filings for Q4 2017.